home / stock / ikna / ikna quote
Last: | $1.70 |
---|---|
Change Percent: | -0.6% |
Open: | $1.69 |
Close: | $1.70 |
High: | $1.73 |
Low: | $1.6735 |
Volume: | 127,350 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.7 | $1.69 | $1.7 | $1.73 | $1.6735 | 127,350 | 07-26-2024 |
$1.68 | $1.6806 | $1.68 | $1.71 | $1.68 | 80,345 | 07-25-2024 |
$1.67 | $1.73 | $1.67 | $1.73 | $1.65 | 42,515 | 07-24-2024 |
$1.68 | $1.6602 | $1.68 | $1.72 | $1.6602 | 30,002 | 07-23-2024 |
$1.675 | $1.67 | $1.675 | $1.69 | $1.6516 | 49,242 | 07-22-2024 |
$1.66 | $1.7 | $1.66 | $1.7 | $1.63 | 136,418 | 07-19-2024 |
$1.67 | $1.69 | $1.67 | $1.72 | $1.67 | 86,233 | 07-18-2024 |
$1.7 | $1.68 | $1.7 | $1.75 | $1.68 | 53,276 | 07-17-2024 |
$1.725 | $1.71 | $1.725 | $1.77 | $1.71 | 83,903 | 07-16-2024 |
$1.7 | $1.74 | $1.7 | $1.7794 | $1.69 | 126,246 | 07-15-2024 |
$1.71 | $1.69 | $1.71 | $1.73 | $1.68 | 198,896 | 07-12-2024 |
$1.65 | $1.63 | $1.65 | $1.69 | $1.63 | 84,258 | 07-11-2024 |
$1.62 | $1.61 | $1.62 | $1.65 | $1.6 | 135,452 | 07-10-2024 |
$1.6 | $1.63 | $1.6 | $1.65 | $1.6 | 138,765 | 07-09-2024 |
$1.63 | $1.64 | $1.63 | $1.68 | $1.63 | 137,176 | 07-08-2024 |
$1.66 | $1.63 | $1.66 | $1.68 | $1.63 | 110,117 | 07-05-2024 |
$1.63 | $1.63 | $1.63 | $1.65 | $1.62 | 76,599 | 07-04-2024 |
$1.63 | $1.63 | $1.63 | $1.65 | $1.62 | 76,599 | 07-03-2024 |
$1.63 | $1.65 | $1.63 | $1.65 | $1.61 | 204,536 | 07-02-2024 |
$1.65 | $1.61 | $1.65 | $1.69 | $1.6 | 316,167 | 07-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strategic options to maximize shareholder value BOSTON, May 28, 2024 (G...
Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strategic options to maximize shareholder value BOSTON, May 28, 2024 (G...
Strong financial position with $157.3 million; runway into 2H 2026 IK-930 program on track to deliver clinical update in 2H 2024 IK-595 program continues dose escalation in patients with RAS and RAF mutant cancers BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, In...